Hereditary Angioedema

Pharming Group will report its Q3 2025 financial results and provide a business update on November 6th. Investors will focus on Ruconest® performance amid competitive HAE therapies and Pharming’s ability to maintain market share. The update will detail R&D pipeline progress, strategic initiatives including collaborations/acquisitions, and capital allocation. Analysts anticipate insights into revenue growth, expense management, and pipeline advancement’s impact on investor sentiment and future prospects. Guidance on full-year performance and strategic priorities will also be closely watched.